Terminated PHASE1 INTERVENTIONAL NCT00099723

The Effect of a Probiotic on Hepatic Steatosis

Sponsor: VSL Pharmaceuticals

Interventions VSL#3

Updated 5 times since 2017 Last updated: Feb 10, 2010 Started: Oct 31, 2004 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The hypothesis that probiotics would reduce hepatic steatosis in humans was not supported

Other Fatty Liver trials with similar outcome

Browse all Fatty Liver trials

This PHASE1 trial investigates Fatty Liver and is currently terminated or withdrawn. VSL Pharmaceuticals leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

VSL Pharmaceuticals

Data source: VSL Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States